|
|
|
|
|
Doxazosin
drug data and news
Doxazosin drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Doxazosin | ||
| Brand Names/Synonyms | Alfadil; CARDURA; Cardenalin; Cardular; Cardura; Cardura-1; Cardura-2; Cardura-4; Carduran; Diblocin; Doxazosin mesylate; Normothen; Supressin | ||
| Indication | For treatment and management of Hypertension and urinary obstruction symptoms of BPH | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Doxazosin is an alpha-adrenergic blocking agent used to treat hypertension and benign prostatic hyperplasia. Accordingly, Doxazosin is a selective inhibitor of the alpha1 subtype of alpha adrenergic receptors. In the human prostate, Doxazosin antagonizes phenylephrine (alpha1 agonist)-induced contractions, in vitro, and binds with high affinity to the alpha1c adrenoceptor, which is thought to be the predominant functional type in the prostate. Studies in normal human subjects have shown that Doxazosin competitively antagonized the pressor effects of phenylephrine (an alpha1 agonist) and the systolic pressor effect of norepinephrine. The antihypertensive effect of Doxazosin results from a decrease in systemic vascular resistance and the parent compound Doxazosin is primarily responsible for the antihypertensive activity. | ||
| Mechanism Of Action | Doxazosin acts by inhibiting the postsynaptic alpha(1)-adrenoceptors on vascular smooth muscle. This inhibits the vasoconstrictor effect of circulating and locally released catecholamines (epinephrine and norepinephrine), resulting in peripheral vasodilation. | ||
| Doxazosin News (When available) |
Recovery Of Abnormal Ejaculation By Intermittent Tamsulosin ... Feb 28, 2006 Pfizer's Norvasc reduces cardiovascular events Feb 8, 2006 Cardiovascular Outcomes in High-Risk Hypertensive Patients ... Feb 8, 2006 Pfizer's Norvasc reduces cardiovascular events Feb 8, 2006 FAMILY DOCTOR: New drugs can help reduce so many nighttime trips ... Dec 7, 2005 MANAGEMENT OF BENIGN PROSTATIC HYPERPLASIA Dec 7, 2005 New Data Show Hypertensive Patients Taking Norvasc-Based Regimen ... Nov 13, 2005 'Water pill' recommended first for blood pressure Sep 11, 2005 ASCOT Trial - Amlodipine Reduces Cardiovascular Mortality Sep 7, 2005 Living with benign prostatic hyperplasia Jun 21, 2005 Living with benign prostatic hyperplasia Jun 21, 2005 Diuretics Are Color Blind Apr 5, 2005 Reaffirmation of Istin's Therapeutic Benefits to Patients After ... Mar 11, 2005 Case 7-2005 — A 59-Year-Old Woman with an Incidentally ... Mar 9, 2005 | ||
| Dosage Forms | oral tablets | ||
| Drug_Category | Vasodilator Agents; Antihypertensive Agents; Anticholesteremic Agents; Alpha-adrenergic Blocking Agents; ATC:C02CA04 | ||
| Absorption | 65% | ||
| Interactions | Most (98%) of plasma doxazosin is protein bound. In vitro data in human plasma indicate that doxazosin mesylate has no effect on protein binding of digoxin, warfarin, phenytoin or indomethacin. There is no information on the effect of other highly plasma protein bound drugs on doxazosin binding. Doxazosin mesylate has been administered without any evidence of an adverse drug interaction to patients receiving thiazide diuretics, beta-blocking agents, and nonsteroidal anti-inflammatory drugs. In a placebo-controlled trial in normal volunteers, the administration of a single 1 mg dose of doxazosin on day 1 of a four-day regimen of oral cimetidine (400 mg twice daily) resulted in a 10% increase in mean AUC of doxazosin (p=0.006), and a slight but not statistically significant increase in mean Cmax and mean half-life of doxazosin. The clinical significance of this increase in doxazosin AUC is unknown. In clinical trials, doxazosin mesylate tablets have been administered to patients on a variety of concomitant medications; while no formal interaction studies have been conducted, no interactions were observed. Doxazosin mesylate tablets have been used with the following drugs or drug classes: 1. Analgesic/anti-inflammatory (e.g., acetaminophen, aspirin, codeine and codeine combinations, ibuprofen, indomethacin). 2. Antibiotics (e.g., erythromycin, trimethoprim and sulfamethoxazole, amoxicillin). 3. Antihistamines (e.g., chlorpheniramine). 4. Cardiovascular agents (e.g., atenolol, hydrochlorothiazide, propranolol). 5. Corticosteroids. 6. Gastrointestinal agents (e.g., antacids). 7. Hypoglycemics and endocrine drugs. 8. Sedatives and tranquilizers (e.g., diazepam). 9. Cold and flu remedies. | ||
| Toxicity | hypotension, LD50 of doxazosin is greater than 1000 mg/kg in mice and rats | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | [4-(4-amino-6,7-dimethoxy-quinazolin-2-yl)piperazin-1-yl]-(2,5-dioxabicyclo[4.4.0]deca-6,8,10-trien-4-yl)methanone | ||
| Chemical Formula | C23H25N5O5 | ||
| Molecular Weight | 451.475 g/mol | ||
| Smiles String | COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4COC5=CC=CC=C5O4)N)OC | ||
| Melting Point | 289-290°C | ||
| Water Solubility | 24 mg/L | ||
| State | Solid | ||
| LogP/Hphobicity | 1.838 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Hepatic | ||
| Half Life | 22 hours | ||
| Protein Binding [%] | 98% | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/car1069.shtml http://www.drugs.com/cons/Doxazosin.html http://www.rxlist.com/cgi/generic/doxazo.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00474 | ||
| CAS Registry Number | 74191-85-8 | ||
| KEGG Compound ID | C06970 | ||
| PubChem ID | SID:64296 | ||
| PharmGKB ID | PA449407 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 2243217 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |